Characterization of a universal screening approach for congenital CMV infection based on a highly-sensitive, quantitative, multiplex real-time PCR assay.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 30 07 2019
accepted: 12 12 2019
entrez: 10 1 2020
pubmed: 10 1 2020
medline: 6 5 2020
Statut: epublish

Résumé

The majority of congenital cytomegalovirus (cCMV) infections are asymptomatic at birth and therefore not diagnosed. Approximately 10-15% of these infants develop late-onset hearing loss and other developmental disorders. Implementation of a universal screening approach at birth may allow early initiation of symptomatic interventions due to a closer follow-up of infants at risk and offers the opportunity to consider treatment of late-onset disease. Real-time PCR assays for the detection of CMV DNA in buccal swab samples demonstrated feasibility and good clinical sensitivity in comparison to a rapid culture screening assay. Because most cCMV infections remain asymptomatic, a universal screening assay that stratifies CMV infected infants according to low and high risk of late-onset cCMV disease could limit the parental anxiety and reduce follow-up costs. We therefore developed and characterized a screening algorithm based on a highly-sensitive quantitative real-time PCR assay that is compatible with centralized testing of samples from universal screening and allows to determine CMV DNA load of saliva samples either as International Units (IU)/ml saliva or IU/105 cell equivalents. 18 of 34 saliva samples of newborns that tested positively by the screening algorithm were confirmed by detection of CMV DNA in blood and/or urine samples obtained during the first weeks of life. All screening samples that could not be confirmed had viral loads of <2.3x105 IU/ml saliva (median: 6.8x103) or 1.3x105 IU/105 cell equivalents (median: 4.0x102). The viral load of screening samples with confirmed cCMV infection ranged from 7.5x102 to 8.2x109 IU/ml saliva (median: 9.3x107) or 1.5x102 to 5.6x1010 IU/105 cell equivalents (median: 3.5x106). Clinical follow-up of these newborns with confirmed cCMV infection should reveal whether the risk of late-onset cCMV disease correlates with CMV DNA load in early life saliva samples and whether a cut-off can be defined identifying cCMV infected infants with or without risk for late-onset cCMV disease.

Identifiants

pubmed: 31917817
doi: 10.1371/journal.pone.0227143
pii: PONE-D-19-21434
pmc: PMC6952102
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0227143

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur J Pediatr. 2015 Aug;174(8):1117-21
pubmed: 25743117
Rev Med Virol. 2007 Sep-Oct;17(5):355-63
pubmed: 17542052
Rev Soc Bras Med Trop. 2015 Mar-Apr;48(2):206-7
pubmed: 25992937
Pediatr Infect Dis J. 2019 May;38(5):520-524
pubmed: 30199483
J Infect Dis. 2018 Apr 23;217(10):1612-1615
pubmed: 29401303
Pediatr Infect Dis J. 2015 May;34(5):536-7
pubmed: 25876092
Rev Med Virol. 2014 Sep;24(5):291-307
pubmed: 24760655
Front Pediatr. 2016 Aug 31;4:93
pubmed: 27630978
Pediatrics. 2017 Feb;139(2):
pubmed: 28049114
J Infect Dis. 2019 Oct 22;220(11):1790-1796
pubmed: 31310307
Open Forum Infect Dis. 2015 Dec 09;3(1):ofv193
pubmed: 26817022
J Clin Virol. 2006 Jul;36(3):228-30
pubmed: 16750653
J Clin Virol. 2019 Jun;115:32-36
pubmed: 30959324
BMC Infect Dis. 2014 Nov 13;14:569
pubmed: 25391640
Infection. 2012 Apr;40(2):181-4
pubmed: 22350961
JAMA Pediatr. 2016 Dec 1;170(12):1173-1180
pubmed: 27723885
JAMA. 2010 Apr 14;303(14):1375-82
pubmed: 20388893
J Clin Virol. 2019 Aug;117:33-36
pubmed: 31176209
Arch Dis Child. 2019 Jun;104(6):559-563
pubmed: 30472664
J Virol. 2017 May 26;91(12):
pubmed: 28381570
PLoS One. 2013 Apr 16;8(4):e61703
pubmed: 23613907
Clin Infect Dis. 2017 Aug 1;65(3):398-404
pubmed: 28419213
Lancet Infect Dis. 2017 Jun;17(6):e177-e188
pubmed: 28291720
J Infect Dis. 2019 Apr 16;219(9):1398-1406
pubmed: 30535363
Expert Rev Anti Infect Ther. 2017 May;15(5):417-419
pubmed: 28277819
Arch Dis Child Fetal Neonatal Ed. 2013 Mar;98(2):F182
pubmed: 22874907
J Infect Dis. 1993 Jun;167(6):1433-6
pubmed: 8388905
J Clin Virol. 2014 Aug;60(4):361-6
pubmed: 24881490
Rev Med Virol. 2011 Jul;21(4):240-55
pubmed: 21674676
J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):e160-e162
pubmed: 29860410
PLoS One. 2009 Sep 10;4(9):e6985
pubmed: 19746164
Ital J Pediatr. 2017 Apr 17;43(1):38
pubmed: 28416012
J Pediatr. 2017 May;184:57-61.e1
pubmed: 28237380
N Engl J Med. 2011 Jun 2;364(22):2111-8
pubmed: 21631323

Auteurs

Angela Nagel (A)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Erlangen, Germany.

Emmanouela Dimitrakopoulou (E)

Department of Otorhinolaryngology, Head and Neck Surgery, Division of Phoniatrics and Pediatric Audiology, St. Elisabeth-Hospital, Ruhr University Bochum, Bochum, Germany.

Norbert Teig (N)

Department of Pediatrics, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.

Peter Kern (P)

Department of Gynecology, St. Elisabeth-Hospital, Ruhr University Bochum, Bochum, Germany.

Thomas Lücke (T)

Department of Pediatrics, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.

Dariusz Michna (D)

Department of Pediatrics, Elisabeth-Hospital Essen, Germany.

Klaus Korn (K)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Erlangen, Germany.

Philipp Steininger (P)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Erlangen, Germany.

Khalid Shahada (K)

Audiology and Balance Center, Hamad Medical Corporation, Doha, Qatar.

Katrin Neumann (K)

Department of Otorhinolaryngology, Head and Neck Surgery, Division of Phoniatrics and Pediatric Audiology, St. Elisabeth-Hospital, Ruhr University Bochum, Bochum, Germany.

Klaus Überla (K)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH